

REVIEW ARTICLE

Korean Skincare (K-Beauty): Science vs Hype

A Dermatology Review of Ingredients, Routines, and Formulation Science



Dr. Minu Liz Mathew¹, MBBS, MD (DVL) . Rejeesh Menon MD ²

¹Board-Certified Dermatologist & Chief Dermatologist, [DermaVue Skin & Plastic Surgery, Lasers & Hair Transplant](#)

10+ years clinical & cosmetic dermatology · IADVL Registered · Cochin Dermatological Society
[RealSelf Verified](#) · Internationally recognized procedural dermatologist, South India

² Elson S. Floyd College of Medicine, Washington State University, WA, USA

Correspondence: rejeesh.menon@wsu.edu



Published: February 10, 2026



~5,800 words



22 min read

ABSTRACT

The global phenomenon of Korean skincare merits rigorous scientific scrutiny, and the evidence reveals a landscape far more nuanced than either its most fervent proponents or dismissive critics suggest. Several core K-beauty principles — daily broad-spectrum photoprotection, barrier-centric hydration, and gentle cleansing — rest on solid dermatological foundations. Specific ingredients such as niacinamide and *Centella asiatica* are supported by credible clinical trial data. Yet the multi-step ritual itself, the majority of “hero” ingredients, and many trending practices lack the controlled human evidence needed to justify their claims. This review examines the clinical evidence, formulation science, and regulatory context behind K-beauty, offering clinicians a framework for distinguishing therapeutic potential from marketing spectacle.

Introduction

Korean skincare's rise from regional practice to a global industry generating over **\$10 billion annually** coincides with an era of unprecedented consumer access to ingredient information — and unprecedented vulnerability to pseudoscientific marketing. The physician's obligation is clear: evaluate these claims through the same lens applied to any therapeutic intervention. What follows is an attempt to do so, ingredient by ingredient, practice by practice, and claim by claim.

The Multi-Step Routine: Sound Principles, Weak Comparative Evidence

The signature “10-step Korean skincare routine” deserves immediate demystification. **This construct was coined for Western audiences by Charlotte Cho (Soko Glam) in a 2014 article for *Into The Gloss*** — it is not a faithful representation of Korean practice. A 2015 Korean Ministry of Food and Drug Safety survey of 892 women found the average Korean woman uses approximately eight product types across morning and evening routines combined. A 2021 Kantar survey of 1,500 Korean women found 28% used only three products in their morning routine. Korea itself has moved toward “Skip-Care” — simplifying regimens to reduce irritation risk.

The [barrier biology argument](#) for product layering is more complex than marketing suggests. The stratum corneum functions as a “bricks and mortar” system: corneocytes embedded in lamellar lipid bilayers composed of **ceramides (~50%), cholesterol (~25%), and free fatty acids (~15%)**. Barrier integrity depends on maintaining this architecture, the [acid mantle \(pH 4.0–5.8\)](#), and adequate hydration. [Transepidermal water loss \(TEWL\)](#) serves as the objective measure of barrier function.

From a percutaneous absorption standpoint, the first product applied to clean skin enjoys optimal access to the stratum corneum. Each subsequent layer faces a modified surface: the prior product's film, potential pH conflicts between actives, and a saturation curve that imposes di-

minishing returns. **No randomized controlled trial has demonstrated that a 10-step regimen produces superior clinical outcomes compared to a well-formulated 3–4 step protocol** (cleanser, active treatment, moisturizer, sunscreen). The single controlled study comparing a five-product “advanced routine” to a two-product “simple routine” ([Merinville et al., *J Clin Aesthet Dermatol*, 2019](#), n=49) did show statistically significant improvements in hydration, roughness, and wrinkle depth favoring the advanced approach — but this was a short-term, industry-funded trial with a small sample.

CLINICAL KEY POINT

Multiple product layering introduces concrete risks. Each additional formulation increases cumulative exposure to preservatives, surfactants, and fragrances — [known triggers for allergic contact dermatitis](#). The average woman using 12 personal care products daily encounters approximately 168 unique chemical ingredients. Korean dermatologists themselves have reported increased presentations of iatrogenic barrier compromise.

The [double cleansing principle](#) — oil-based removal of lipophilic impurities followed by water-based cleansing — has sound chemistry (“like dissolves like”), but no controlled trial compares it against thorough single cleansing for dermatologic outcomes. Over-cleansing with harsh surfactants (particularly [sodium lauryl sulfate](#)) demonstrably damages stratum corneum proteins and lipids, increasing TEWL and impairing barrier recovery.

The scientifically defensible conclusion is that consistency, gentleness, targeted active delivery, and sun protection matter far more than step count. A streamlined regimen of 3–5 products can deliver the same benefits attributed to elaborate routines, with less risk of sensitization or barrier disruption.

Ingredient Evidence: From Robust to Absent

Niacinamide: The Best-Validated K-Beauty Active

STRONG EVIDENCE

Among all ingredients popularized by Korean skincare, **niacinamide (vitamin B3)** possesses **the strongest and most independently replicated evidence base**. As a precursor to NAD⁺/NADP⁺ coenzymes, it operates through multiple well-characterized mechanisms: [stimulation of ceramide and free fatty acid synthesis](#) in the stratum corneum, inhibition of melanosome transfer from melanocytes to keratinocytes, [reduction of sebum excretion](#), suppression of NF-κB-mediated inflammation, and facilitation of UV-induced DNA repair.

The clinical evidence is unusually robust for a cosmeceutical ingredient. Landmark split-face RCTs by [Bissett et al. \(*Dermatol Surg*, 2004; *Int J Cosmet Sci*, 2005; n=50 each\)](#) demonstrated that **5% niacinamide** significantly reduced fine lines, hyperpigmented spots, skin sallowness, and improved elasticity over 12 weeks compared to vehicle. [Navarrete-Solís et al. \(*Int J Dermatol*, 2011\)](#) showed 4% niacinamide matched **4% hydroquinone** for melasma in a double-blind split-face trial, with fewer side effects. [Draelos et al.](#) confirmed that 2% niacinamide significantly reduces sebum excretion in controlled trials. For acne, 4% niacinamide gel has demonstrated efficacy comparable to 1% clindamycin without the risk of antibiotic resistance.

Optimal concentration: 2–5% for cosmetic applications. The evidence-to-marketing gap is minimal — niacinamide claims are largely substantiated.

***Centella asiatica* (CICA): Moderate-to-Strong Evidence** MODERATE-STRONG

Centella asiatica has the second-strongest evidence base among K-beauty ingredients. Its active triterpenoid saponins — asiaticoside, madecassoside, asiatic acid, and madecassic acid — act through TGF-β/Smad-driven collagen synthesis, NF-κB pathway attenuation, and VEGF-mediated angiogenesis. A [systematic review by Hongsing et al. \(2022\)](#) found benefit across burn wounds, diabetic ulcers, hypertrophic scars, and split-thickness skin grafts. A [network meta-analysis by Waranuch et al. \(*J Cosmet Sci*, 2020\)](#) of five double-blind RCTs (n=172 Asian females) found *Centella* improved lip and periocular wrinkles and **may be comparable to tretinoin with superior hydration outcomes**. A [meta-analysis of 10 studies on acne](#) (7 RCTs, 3 observational, 875 participants) showed a pooled mean difference of –0.54 in acne lesion count favoring *Centella asiatica*.

The principal limitation is lack of extract standardization across commercial products — triterpenoid concentrations in consumer “CICA creams” vary widely from those used in trials.

Snail Mucin: Biologically Plausible, Clinically Under-Replicated MODERATE (LOW)

Snail secretion filtrate (SCA) from *Cryptomphalus aspersa* contains glycosaminoglycans, allantoin, glycolic acid, copper peptides, and antioxidant enzymes. Clinical data includes a 14-week split-face RCT by [Fabi et al. \(*J Drugs Dermatol*, 2013, n=25\)](#) showing improvement in periocular rhytides, and a 3-month double-blinded RCT by [Lim et al. \(*J Clin Aesthet Dermatol*, 2020, n=50\)](#) showing improvements in roughness, brightness, and barrier function.

However, **nearly all published clinical studies are funded by Cantabria Labs**, the manufacturer of patented SCA preparations. Independent replication is sparse. Consumer K-beauty “snail mucin” products may differ substantially from standardized extracts used in trials. A [2024 review in *J Cosmet Dermatol*](#) noted significant limitations in the existing evidence base.

Fermented Ingredients (Galactomyces/Saccharomyces) MODERATE (LOW)

[Galactomyces ferment filtrate \(GFF/Pitera™\)](#) operates through aryl hydrocarbon receptor (AHR) agonism — upregulating filaggrin, caspase-14, and tight junction claudins — and NRF2 activation for antioxidant defense. An [11-year longitudinal study by Miyamoto et al. \(*J Clin Med*, 2023, n=86\)](#) reported that 12-month GFF treatment reversed measurable skin aging parameters.

The critical limitation: virtually all published evidence originates from P&G (manufacturer of SK-II). No large independent RCTs exist. The fundamental question — does fermentation genuinely improve bioavailability over unfermented substrates? — has never been tested in comparative clinical trials, despite strong mechanistic plausibility.

The Hyperpigmentation Triad: Arbutin, Tranexamic Acid, and Licorice Root

Korean dermatology’s multi-pathway approach to pigmentation — combining gentler agents targeting different steps of melanogenesis — represents a philosophically distinct strategy from Western reliance on hydroquinone as first-line therapy.

Tranexamic acid has the strongest evidence in this category. **MODERATE-STRONG** As a plasmin inhibitor, it reduces keratinocyte-driven melanocyte stimulation. [Ebrahimi and Naeini \(J Res Med Sci, 2014\)](#) demonstrated topical 3% TXA comparable to 3% hydroquinone plus 0.01% dexamethasone in a split-face RCT. A meta-analysis in *Acta Dermato-Venereologica* confirmed TXA demonstrates similar efficacy to hydroquinone with fewer adverse effects. Oral TXA (250 mg BID) holds even stronger evidence for melasma.

Arbutin (α -arbutin preferred) inhibits tyrosinase competitively. **MODERATE** A trial of 120 melasma patients found 3% arbutin cream achieved >50% MASI reduction in 54% of subjects. A combination serum containing 4% α -arbutin with 2% niacinamide and 2–3% tranexamic acid demonstrated non-inferiority to 4% hydroquinone.

Glabridin (from licorice root) inhibits tyrosinase and targets MITF transcription. **WEAK-MODERATE** The in vitro claim of “16× more effective than hydroquinone” derives from enzymatic assays and **does not translate to clinical reality**. Few adequately powered human trials exist.

The Korean combination approach (TXA + arbutin + niacinamide) has scientific rationale for multi-pathway melanogenesis inhibition and offers a safer long-term alternative to hydroquinone, particularly for maintenance therapy.

Trending Ingredients with Insufficient Human Evidence

Mugwort (*Artemisia*) **WEAK / PRECLINICAL ONLY** represents perhaps the largest claim-to-evidence gap in K-beauty. Despite aggressive marketing as a soothing, anti-inflammatory agent, **virtually no controlled human clinical trials exist** for topical cosmetic application. [Anti-inflammatory activity](#) (COX-2 and iNOS suppression) has been demonstrated only in cell cultures and animal models. The [AHR/OVOL1/filaggrin pathway](#) was characterized entirely in HaCaT keratinocytes. Additionally, [mugwort is a known IgE allergen](#) with cross-reactivity to birch pollen.

Ginseng extracts **WEAK-MODERATE** have [strong in vitro data](#) — ginsenoside Rb1 increases type I collagen production, Rg1 suppresses MMP-1 — but human clinical trials are few, small (n=20–24), and often use combination products preventing single-ingredient attribution.

Green tea/EGCG **MODERATE (CONTRADICTIONARY)** presents a mixed picture. Oral catechins showed benefits in one well-designed RCT (Heinrich et al., *J Nutr*, n=60), but two subsequent RCTs by Farrar et al. (*AJCN*, 2015; *JAAD*, 2018) **failed to confirm UV-protective effects** in humans. Topical EGCG faces severe formulation stability challenges — the compound oxidizes readily.

Propolis **WEAK-MODERATE** shows moderate evidence for acne (Mazzarello et al., 2018: 20% propolis cream reduced acne severity by 66.7% vs. 49.7% for erythromycin), but carries well-documented allergy risks. **Rice bran** extracts have largely preclinical support.

Hyaluronic Acid Multi-Weight Layering: Sound Concept, Unproven Ritual

K-beauty popularized the idea of layering hyaluronic acid products of different molecular weights to achieve “multi-depth hydration.” The underlying penetration science is legitimate. Raman micro-imaging by Essendoubi et al. (*Skin Res Technol*, 2016) confirmed that low molecular weight HA (20–300 kDa) penetrates the stratum corneum while high molecular weight HA (>1,000 kDa) remains on the surface. Pavicic et al. (*J Drugs Dermatol*, 2011, n=76) demonstrated that **50 kDa HA achieved significant wrinkle depth reduction** that higher MW formulations did not, in a 60-day RCT comparing five molecular weights.

However, **no study has tested the specific K-beauty practice of sequential application of separate MW products**. All existing evidence uses pre-mixed multi-weight formulations. A further concern: very low MW HA (<20 kDa) may activate TLR2/TLR4 receptors, triggering pro-inflammatory signaling — a risk rarely discussed in consumer contexts.

Korean Sunscreen Science Genuinely Outpaces American Options

If any domain of K-beauty deserves unqualified respect from clinicians, it is photoprotection. **Korean (and more broadly, East Asian and European) sunscreen formulation science is**

objectively superior to what is available in the United States, owing entirely to regulatory differences rather than scientific capability.

The US FDA classifies sunscreens as OTC drugs requiring GRASE determination. [No new UV filter has been approved since 1996](#) (avobenzene). The US permits only 16 UV filters, with only zinc oxide and titanium dioxide classified as Category I GRASE. By contrast, Korea and the EU approve **30+ UV filters**, including next-generation broad-spectrum agents:

Bemotrizinol (Tinosorb S): oil-soluble organic filter covering both UVB (310 nm) and UVA (340 nm), extremely photostable, MW 627.81 g/mol — too large for meaningful systemic absorption. A significant regulatory development occurred in December 2025 when the [FDA issued a proposed order for bemotrizinol](#) — potentially the first new sunscreen active approved in the US in three decades.

Bisocetrizole (Tinosorb M): a hybrid absorber-reflector-scatterer with approximately 0.01% dermal penetration in human studies and no estrogenic effects. **Diethylamino hydroxybenzoyl hexyl benzoate (Uvinul A Plus)**: lightweight, high UVA absorption.

[Kolmar Korea's patented UV-DUO PLUS technology](#) — a hybrid composite system encapsulating inorganic particles with organic UV filters — demonstrated a **24.8% improvement in long-wavelength UVA protection at 400 nm** compared to conventional formulations in clinical testing, achieving SPF 50+ PA++++ classification. The [PA grading system](#) itself, based on Persistent Pigment Darkening (PPD) testing, provides consumers with quantitative UVA protection information that the US “Broad Spectrum” label (a binary pass/fail requiring only critical wavelength ≥ 370 nm) does not.

The cosmetic elegance of Korean sunscreens is not trivial from a public health standpoint. **Sunscreen that is pleasant to wear gets used consistently**. The Hughes et al. landmark RCT (*Ann Intern Med*, 2013, n=903, 4.5-year follow-up) demonstrated that daily sunscreen users showed **24% less skin aging**. Compliance drives outcomes, and formulation elegance drives compliance.

FEATURE	KOREA (MFDS)	UNITED STATES (FDA)	EUROPEAN UNION
Sunscreen classification	Functional cosmetic	OTC drug	Cosmetic
Approved UV filters	~30+	16	30+
New ingredient timeline	7 days – 6 months	Years to decades	SCCS review (months)
UVA rating system	PA++++ (quantitative)	“Broad Spectrum” (pass/fail)	UVA-PF / PPD
Animal testing	Banned	Permitted	Banned

Sheet Masks, “Glass Skin,” and Slugging

Sheet masks exploit the well-established principle that occlusion enhances hydrophilic molecule penetration — [one study measured up to 40% increased transdermal delivery](#) of hyaluronic acid under occlusion. Peak penetration occurs within 15–20 minutes. However, [prolonged occlusion paradoxically weakens barrier function](#): a clinical study showed that sustained mask-wearing reduced stratum corneum hydration post-removal and increased TEWL on challenge. No comparative trial has demonstrated superiority of sheet masks over well-formulated leave-on serums for any long-term endpoint. **Benefits are transient and primarily cosmetic.**

Slugging (petrolatum occlusion) has a surprisingly robust evidence base. Czarnowicki et al. (*J Allergy Clin Immunol*, 2016, n=49) demonstrated that 48-hour petrolatum occlusion significantly upregulated antimicrobial peptides, innate immune genes, and **barrier differentiation markers (filaggrin, loricrin)** — establishing that petrolatum is not biologically inert but actively modulates barrier repair. For barrier-compromised skin, thin petrolatum application is well-supported. However, the viral trend lacks diagnostic nuance — occlusion creates conditions favorable to *Malassezia* overgrowth and folliculitis, particularly in humid environments or on acne-prone skin.

“**Glass skin**” as a cosmetic goal conflates achievable barrier optimization with an unrealistic aesthetic standard. Consistent hydration, gentle exfoliation, and photoprotection measurably improve texture and luminosity. But poreless, filtered-appearing skin is substantially genetic. The pursuit itself has driven counterproductive product accumulation — with clinicians reporting increased iatrogenic barrier compromise in patients chasing this trend.

pH-Adjusted Cleansing: Evidence-Based, With Caveats

K-beauty’s emphasis on pH 5.5 cleansers reflects genuine barrier biology. The acid mantle regulates serine protease activity, ceramide-generating enzymes, antimicrobial peptide function, and microbiome composition. [Schmid-Wendtner and Korting \(*Skin Pharmacol Physiol*, 2006\)](#) established that alkaline soaps (pH 9–10) significantly elevate skin pH without normalization even 90 minutes post-wash. [Lee et al. \(2009\)](#) showed pH 8 products significantly increased TEWL under challenge compared to pH 5 products.

However, a critical nuance: **pH alone does not guarantee mildness.** [Hawkins et al. \(*Int J Cosmet Sci*, 2021\)](#) found that anionic surfactants at skin-matched pH 5.5 actually caused *more* dryness and irritation than the same surfactants at neutral pH 7.0 — because keratin charge increases at lower pH, enhancing anionic surfactant binding to skin proteins. **The surfactant system matters as much as pH.** A gentle syndet-based cleanser in the pH 4.5–6.5 range represents the evidence-based recommendation.

Ceramide Formulations: Genuine Barrier Repair Science

The evidence for ceramide-based barrier repair is among the strongest in cosmetic dermatology. Foundational work by Mao-Qiang, Man, and Yang established that **all three physiologic lipids — ceramides, cholesterol, and free fatty acids — must be present together** for optimal barrier recovery. The ceramide-dominant 3:1:1 molar ratio accelerated recovery in young skin, though Mao-Qiang et al. found that **cholesterol-dominant ratios were more effective in aged skin** — a clinically important distinction rarely discussed.

[EpiCeram](#) (ceramide-dominant 3:1:1 emulsion) demonstrated efficacy in a 50-center open-label study of 207 atopic dermatitis patients, with approximately 50% achieving IGA success (Kircik et al., *JCAD*, 2011). [Elias and Sugarman](#) (*Ann Allergy Asthma Immunol*, 2018) emphasized that physiologic lipids should be provided at **≥5% final concentration** in the 3:1:1 ratio, and that synthetic pseudoceramides appear to function equivalently to natural ceramides.

CLINICAL WARNING

Many commercial products marketing “ceramides” contain trivially low concentrations and omit cholesterol or free fatty acids entirely, providing no true physiologic barrier repair. Effective ceramide therapy requires the **complete lipid trio at functional concentrations** — a specification most Korean (and Western) consumer products fail to disclose.

Microbiome Claims: Scientific Promise Outpacing Products

The skin microbiome has become a major K-beauty marketing narrative. The underlying science is legitimate: [topical prebiotics have demonstrated measurable microbiome modulation in controlled human trials](#). A Korean RCT of topical galacto-oligosaccharide serum (n=60, 8 weeks) showed significantly improved water-holding capacity, reduced TEWL, decreased *S. aureus* populations, and increased Shannon diversity.

However, most K-beauty “probiotic” products contain **postbiotics (ferment lysates, filtrates)** — not live microorganisms, which are unstable in preserved cosmetic formulations. Marketing frequently conflates prebiotics, probiotics, and postbiotics. While the category holds genuine scientific promise, **individual K-beauty products rarely publish product-specific clinical validation**.

Korean and Western Dermatology: Converging More Than Diverging

The philosophical differences between Korean and Western dermatologic practice — prevention versus treatment, combination versus monotherapy, cosmeceutical integration versus

pharmaceutical primacy — are narrowing. The core pharmacopeia is identical. Korean dermatology’s signature contribution is the **combination protocol**: a single clinic session may integrate extraction, neurotoxins, laser, radiofrequency, mesotherapy, and LED therapy. Korean clinics have [pioneered skin boosters \(PDRN/Rejuran\)](#), HIFU for preventive laxity treatment, and exosome-based therapies — though the latter lack FDA approval and have attracted regulatory warnings.

The apparent difference in skin aging between Asian and Western populations reflects **genetics and photoprotection behavior more than skincare ritual**. Nouveau-Richard et al. (*J Dermatol Sci*, 2005) documented wrinkle onset delayed by approximately 10 years in Chinese versus French women — attributable to thicker dermis, higher collagen density, greater melanin content, and consistent sun protection habits.

Home Devices: Clinical-Grade Evidence, Consumer-Grade Gaps

[Clinical-grade LED therapy](#) has Grade B evidence for acne (blue light, 415 nm) and photorejuvenation (red light, 633 nm; near-infrared, 830 nm). However, [home devices “have not been validated by controlled clinical studies”](#) per a *JCAD* systematic review — they operate at lower irradiances with unestablished protocols and treatment durations. Microcurrent for facial muscle “toning” has thin clinical support outside of post-surgical rehabilitation contexts.

Evidence Summary: K-Beauty Ingredients and Practices

INGREDIENT / PRACTICE	EVIDENCE GRADE	INDEPENDENT REPLICATION	CLINICAL UTILITY
Niacinamide (2–5%)	Strong	Yes, multiple labs	High — barrier, brightening, sebum, anti-aging
Daily broad-spectrum SPF	Strong	Yes (Hughes RCT)	High — aging prevention, photoprotection

INGREDIENT / PRACTICE	EVIDENCE GRADE	INDEPENDENT REPLICATION	CLINICAL UTILITY
Ceramide + cholesterol + FFA	Strong	Yes	High — barrier repair in compromised skin
Centella asiatica (CICA)	Moderate–Strong	Moderate	High for wounds/scars; moderate for anti-aging
Tranexamic acid	Moderate–Strong	Yes	High for melasma
pH-adjusted cleansing	Moderate–Strong	Yes	Moderate — surfactant system equally important
Arbutin (α-arbutin)	Moderate	Moderate	Moderate — gentler HQ alternative
Snail mucin (SCA)	Moderate (low)	Low (industry-funded)	Low–moderate — promising but under-replicated
GFF/Pitera (ferments)	Moderate (low)	Low (industry-funded)	Low–moderate — good mechanisms, weak data
Multi-weight HA	Moderate	Limited	Moderate concept; layering ritual unproven
Green tea/EGCG (topical)	Moderate	Contradictory	Low — stability issues undermine formulations
Propolis (acne)	Moderate	Low	Low–moderate — allergy risk
Sheet masks	Weak	Absent	Low — transient cosmetic benefit only
Multi-step layering (>5 steps)	Weak	Absent	Uncertain — no superiority over simpler regimens
Mugwort (Artemisia)	Weak / Preclinical	Absent	Very low — no human clinical trials

INGREDIENT / PRACTICE	EVIDENCE GRADE	INDEPENDENT REPLICATION	CLINICAL UTILITY
Ginseng (topical)	Weak-Moderate	Low	Low — oral may outperform topical
Rice bran	Weak-Moderate	Minimal	Low — traditional use exceeds clinical evidence
Exosomes (topical)	Low / Preclinical	Absent	Not recommended — regulatory concerns

What Clinicians Should Tell Patients

The physician encountering a patient with an elaborate K-beauty routine need not dismantle it entirely, but should guide toward evidence-informed optimization. The defensible core of Korean skincare — gentle cleansing at physiologic pH, targeted actives (particularly niacinamide and evidence-supported retinoids), ceramide-based barrier repair, and daily broad-spectrum photoprotection — aligns with dermatological best practice regardless of cultural origin.

The excess — the tenth step, the mugwort essence, the snail mucin sheet mask left on for 45 minutes — represents varying degrees of harmless indulgence, wasted expenditure, or active risk.

CONCLUDING ASSESSMENT

Korean skincare’s lasting contribution to global dermatology is not a specific product or step count, but a philosophical reorientation: the idea that skin health is maintained through consistent, preventive care rather than episodic therapeutic intervention. That the barrier deserves protection, not assault. That sunscreen should be cosmetically elegant enough to wear daily. These principles are scientifically sound. The commercial apparatus built around them requires the same skepticism clinicians apply to any intervention where marketing investment dwarfs evidence generation.

References

1. Bissett DL, Oblong JE, Berge CA. Niacinamide: A B vitamin that improves aging facial skin appearance. *Dermatol Surg.* 2005;31(7 Pt 2):860-866. [PubMed](#)
2. Navarrete-Solís J, Castanedo-Cázares JP, Torres-Álvarez B, et al. A double-blind, randomized clinical trial of niacinamide 4% versus hydroquinone 4% in the treatment of melasma. *Dermatol Res Pract.* 2011;2011:379173. [PMC](#)
3. Draelos ZD, Matsubara A, Smiles K. The effect of 2% niacinamide on facial sebum production. *J Cosmet Laser Ther.* 2006;8(2):96-101. [PubMed](#)
4. Hongsing P, et al. A systematic review of randomized controlled trials on efficacy of *Centella asiatica* for wound healing. *J Health Sci Altern Med.* 2022. [Full text](#)
5. Waranuch N, et al. Efficacy and safety of *Centella asiatica* on wrinkles: A systematic review and network meta-analysis. *J Cosmet Sci.* 2020. [PubMed](#)
6. Systematic review and meta-analysis: Efficacy of *Centella asiatica* in treating acne vulgaris. *Biomed J Sci Tech Res.* [Full text](#)
7. Fabi SG, Cohen JL, Peterson JD, et al. The effects of filtrate of the secretion of the *Cryptomphalus aspersa* on photoaged skin. *J Drugs Dermatol.* 2013;12(4):453-457. [PubMed](#)
8. Lim SH, et al. Efficacy and safety of a new cosmeceutical regimen based on snail secretion filtrate. *J Clin Aesthet Dermatol.* 2020;13(5):51-55. [PubMed](#)
9. Suh MK, et al. Snail extract for skin: A review of uses, projections, and limitations. *J Cosmet Dermatol.* 2024. [PubMed](#)
10. Miyamoto K, Inoue Y, Yan X, et al. Galactomyces ferment filtrate potentiates an anti-inflammaging system in keratinocytes. *J Clin Med.* 2022;11(21):6338. [PMC](#)
11. Miyamoto K, et al. Significant reversal of facial wrinkle, pigmented spot and roughness by daily application of galactomyces ferment filtrate — an 11-year longitudinal study. *J Clin Med.* 2023;12(3):1168. [Full text](#)
12. Ebrahimi B, Naeini FF. Topical tranexamic acid as a promising treatment for melasma. *J Res Med Sci.* 2014;19(8):753-757. [PMC](#)
13. Kim K, et al. Anti-inflammatory effects of *Artemisia* leaf extract in mice with contact dermatitis in vitro and in vivo. *Mediators Inflamm.* 2016. [PMC](#)
14. Furue M, et al. Antioxidant *Artemisia princeps* extract enhances filaggrin and loricrin via AHR/OVOL1. *Int J Mol Sci.* 2017. [PMC](#)

15. Yun JW, et al. Anti-skin-aging effects of tissue-cultured mountain-grown ginseng. *J Ginseng Res*. 2022. [PubMed](#)
16. Koch W, et al. Beneficial effects of EGCG in preventing skin photoaging: A review. *Int J Mol Sci*. 2024. [PMC](#)
17. Almuhaideb R. Great green tea ingredient? A narrative review on EGCG for topical dermatology. *Phytother Res*. 2020;34(5):1183-1196. [Full text](#)
18. Komane B, et al. Bee products in dermatology and skin care. *Molecules*. 2020;25(3):556. [PMC](#)
19. Modernizing U.S. sunscreen regulations: How newer filters can improve public health. *J Am Acad Dermatol*. 2025. [PMC](#)
20. FDA Scientific Review: Bemotrizinol OTC000039. December 2025. [FDA](#)
21. Hughes MCB, Williams GM, Baker P, Green AC. Sunscreen and prevention of skin aging: A randomized trial. *Ann Intern Med*. 2013;158(11):781-790. [Abstract](#)
22. Schmid-Wendtner MH, Korting HC. The pH of the skin surface and its impact on the barrier function. *Skin Pharmacol Physiol*. 2006;19(6):296-302. [PDF](#)
23. Lee E, et al. The alkaline pH-adapted skin barrier is disrupted severely by SLS-induced irritation. *Chem Pharm Bull*. 2009. [PubMed](#)
24. Hawkins S, et al. Impact of cleanser pH on maintaining a healthy skin barrier. *JAAD*. 2018;78(2 Suppl 1):AB100. [Abstract](#)
25. Mao-Qiang M, et al. Optimal ratios of topical stratum corneum lipids improve barrier recovery in chronologically aged skin. *J Am Acad Dermatol*. 1997;37(3 Pt 1):403-408. [PubMed](#)
26. Kircik LH, et al. Evaluating clinical use of a ceramide-dominant physiologic lipid-based topical emulsion for atopic dermatitis. *J Clin Aesthet Dermatol*. 2011;4(3):34-40. [PMC](#)
27. Elias PM, Sugarman J. Clinical perspective: Moisturizers vs. barrier repair in atopic dermatitis. *Ann Allergy Asthma Immunol*. 2018. [PMC](#)
28. Czarnowicki T, et al. Petrolatum: Barrier repair and antimicrobial responses underlying this “inert” moisturizer. *J Allergy Clin Immunol*. 2016;137(4):1091-1102. [PubMed](#)
29. Recharla N, et al. Changes in the diversity of human skin microbiota to cosmetic serum containing prebiotics: Results from a randomized controlled trial. *J Microbiol Biotechnol*. 2020;30(10):1525. [PMC](#)
30. Merinville E, et al. Clinical evidences of benefits from an advanced skin care routine in comparison with a simple routine. *J Clin Aesthet Dermatol*. 2019. [PubMed](#)
31. Wunsch A, Matuschka K. Light-emitting diodes in dermatology: A systematic review of randomized controlled trials. *Lasers Med Sci*. 2014. [PMC](#)
32. Ablon G. Phototherapy with light emitting diodes: Treating a broad range of conditions in dermatology. *J Clin Aesthet Dermatol*. 2018;11(2):21-27. [Full text](#)
33. Kolmar Korea UV-DUO PLUS hybrid composite sunscreen technology. *Cosmetics Design Asia*. April 2025. [Full text](#)

34. South Korea functional cosmetic regulation. ChemLinked Cosmetic Database. [Full text](#)

Disclosures: Dr. Minu Liz Mathew is Chief Dermatologist at DermaVue Skin & Plastic Surgery, Lasers & Hair Transplant. No external funding was received for this review. The author has no financial relationships with any Korean skincare brands or manufacturers discussed herein. This review reflects independent clinical and scientific evaluation.

How to cite: Mathew ML. Korean Skincare (K-Beauty): Science vs Hype — A Dermatology Review. *DermaVue Clinical Reviews*. 2026;1(1). Available at: <https://dermavue.com/k-beauty-science-vs-hype-dermatology-review/>

Disclaimer: This review is intended for educational purposes for clinicians and scientifically literate professionals. It does not constitute medical advice for individual patients. Healthcare decisions should involve direct consultation with a qualified dermatologist.

© 2026 DermaVue Skin & Plastic Surgery, Lasers & Hair Transplant · All rights reserved

dermavue.com ·

md@dermavue.com ·

[RealSelf Profile](#)